EMA finds no new safety concerns following Roche pharmacovigilance inspection
The European Medicines Agency has finalized a thorough review of all medicines manufactured by Swiss pharma major Roche (ROG: SIX) that was initiated following a routine pharmacovigilance inspection in early 2012 (The Pharma Letter October 23, 2012), saying that no new safety concerns have been identified.
The 2012 inspection had identified some safety data relating to these medicines that had not previously been provided by Roche. The EMA review examined whether these further data impacted on the balance of benefits and risks of these medicines. Included in this review were 19 centrally-authorized drugs, as well as various medicines that have been nationally approved.
Follows initial inspection by UK’s MHRA
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze